Validation of ERICVA Risk Score as a Predictor of One Year Amputation-Free Survival of Patients with Critical Limb Ischemia.
Adult
Aged
Aged, 80 and over
Amputation, Surgical
Critical Illness
Databases, Factual
Decision Support Techniques
Female
Humans
Ischemia
/ diagnosis
Male
Middle Aged
Peripheral Arterial Disease
/ diagnosis
Predictive Value of Tests
Progression-Free Survival
Reproducibility of Results
Risk Assessment
Risk Factors
Time Factors
Critical Limb Ischemia
ERICVA score
Risk Score
Journal
Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
16
11
2020
revised:
30
01
2021
accepted:
03
02
2021
pubmed:
6
4
2021
medline:
15
12
2021
entrez:
5
4
2021
Statut:
ppublish
Résumé
The ERICVA score was derived to predict amputation-free survival in patients with critical limb ischemia (CLI). It may be a useful tool to stratify patients in trials of novel interventions to treat CLI but, as yet, it has not been externally validated. A prospective database of CLI patients was developed during prescreening of patients for a phase 1 stem cell therapy clinical trial. The primary outcome was amputation free survival (AFS) at 1 year. Both the full ERICVA scale (11 parameters) and simplified ERICVA scale (5 parameters) were validated. Data analysis was performed by calculation of the area under the receiver operating characteristic (ROC) curve examining the predictive value of the scores. The Chi-square test was used to examine the association between risk group and one-year AFS and the cumulative survival of the three risk groups was compared using Kaplan Meier survival curves. A series of 179 CLI patients were included in the analysis. The Chi-square test of independence showed a significant association between the risk group (high, medium and low) and one-year AFS outcome (P = 0.0007). Kaplan-Meier survival curve showed significant difference in one-year AFS between the three risk groups (log-rank P < 0.001). The area under the curve (AUC) was found to be 0.63 and 0.61 for the full and simplified score, respectively. The sensitivity of the full score was 0.44 with specificity of 0.84. The simplified score had a sensitivity of 0.28 and specificity of 0.92. The ERICVA risk score system was found to have a fair validity but cannot be considered reliable as a single predictor of one year AFS of CLI patients. The simplified score had an AUC almost identical to the full score and can accordingly replace the full score.
Sections du résumé
BACKGROUND
BACKGROUND
The ERICVA score was derived to predict amputation-free survival in patients with critical limb ischemia (CLI). It may be a useful tool to stratify patients in trials of novel interventions to treat CLI but, as yet, it has not been externally validated.
METHODS
METHODS
A prospective database of CLI patients was developed during prescreening of patients for a phase 1 stem cell therapy clinical trial. The primary outcome was amputation free survival (AFS) at 1 year. Both the full ERICVA scale (11 parameters) and simplified ERICVA scale (5 parameters) were validated. Data analysis was performed by calculation of the area under the receiver operating characteristic (ROC) curve examining the predictive value of the scores. The Chi-square test was used to examine the association between risk group and one-year AFS and the cumulative survival of the three risk groups was compared using Kaplan Meier survival curves.
RESULTS
RESULTS
A series of 179 CLI patients were included in the analysis. The Chi-square test of independence showed a significant association between the risk group (high, medium and low) and one-year AFS outcome (P = 0.0007). Kaplan-Meier survival curve showed significant difference in one-year AFS between the three risk groups (log-rank P < 0.001). The area under the curve (AUC) was found to be 0.63 and 0.61 for the full and simplified score, respectively. The sensitivity of the full score was 0.44 with specificity of 0.84. The simplified score had a sensitivity of 0.28 and specificity of 0.92.
CONCLUSION
CONCLUSIONS
The ERICVA risk score system was found to have a fair validity but cannot be considered reliable as a single predictor of one year AFS of CLI patients. The simplified score had an AUC almost identical to the full score and can accordingly replace the full score.
Identifiants
pubmed: 33819592
pii: S0890-5096(21)00204-1
doi: 10.1016/j.avsg.2021.02.013
pmc: PMC8600123
pii:
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-178Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
PLoS One. 2013 Jul 02;8(7):e67688
pubmed: 23844064
J Vasc Interv Radiol. 2006 Sep;17(9):1383-97; quiz 1398
pubmed: 16990459
Eur J Vasc Endovasc Surg. 2013 May;45(5):488-96
pubmed: 23434110
Eur J Vasc Endovasc Surg. 2012 May;43(5):540-7
pubmed: 22342695
World J Surg. 2007 Jan;31(1):217-25; discussion 226-7
pubmed: 17171494
Cytotherapy. 2014 Feb;16(2):245-57
pubmed: 24438903
Cytotherapy. 2016 Jun;18(6):712-24
pubmed: 27067609
World J Surg. 2013 Apr;37(4):915-22
pubmed: 23307180
J Transl Med. 2013 Jun 10;11:143
pubmed: 23758736
J Vasc Surg. 2008 Dec;48(6):1464-71
pubmed: 19118735
Eur J Vasc Endovasc Surg. 2016 Jan;51(1):90-9
pubmed: 26602223
J Vasc Surg. 2010 Jan;51(1):230-41
pubmed: 20117502
J Vasc Surg. 2013 Jan;57(1):1-7
pubmed: 23040797
Cytotherapy. 2020 Jun;22(6):313-321
pubmed: 32273232